AbbVie Buying Allergan Isn’t the Right Remedy for the Stock – Barron's

AbbVie Buying Allergan Isn’t the Right Remedy for the Stock  Barron’s

AbbVie is getting a company whose problems resemble its own, an expensive life raft for the 45% premium AbbVie is paying over Allergan’s stock price.

View full coverage on Google News
Source: Google News | AbbVie Buying Allergan Isn’t the Right Remedy for the Stock – Barron's